IRLAB Therapeutics AB (IRLAB A) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cantargia AB

IRLAB Therapeutics AB

Medivir AB

Orexo AB

InDex Pharmaceuticals Holding AB

Cereno Scientific AB

SynAct Pharma AB

Initiator Pharma A/S

Diamyd Medical AB

Guard Therapeutics International AB

Kancera AB

Why is IRLAB Therapeutics AB ?

With a growth in Net Sales of 167.33%, the company declared Very Positive results in Mar 26

RAW MATERIAL COST(Y) Fallen by -103.43% (YoY)
NET SALES(Q) Highest at SEK 39.36 MM
OPERATING PROFIT(Q) Highest at SEK 10.63 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -65.76%, its profits have fallen by -32.3%

Below par performance in long term as well as near term

Along with generating -65.76% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to IRLAB Therapeutics AB should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is IRLAB Therapeutics AB for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

IRLAB Therapeutics AB

-65.88%

-1.83

49.74%

OMX Stockholm 30

28.68%

1.89

15.95%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

125.62%

EBIT Growth (5y)

-0.11%

EBIT to Interest (avg)

-41.40

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-5.36

Sales to Capital Employed (avg)

0.72

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

2.69%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.41

EV to EBIT

-0.90

EV to EBITDA

-0.95

EV to Capital Employed

-3.94

EV to Sales

1.45

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-358.13%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -103.43% (YoY

NET SALES(Q)

Highest at SEK 39.36 MM

OPERATING PROFIT(Q)

Highest at SEK 10.63 MM

OPERATING PROFIT MARGIN(Q)

Highest at 27 %

PRE-TAX PROFIT(Q)

Highest at SEK 9.12 MM

NET PROFIT(Q)

Highest at SEK 9.12 MM

EPS(Q)

Highest at SEK 0.11

-3What is not working for the Company

ROCE(HY)

Lowest at -300.93%

CASH AND EQV(HY)

Lowest at SEK 132.64 MM

Here's what is working for IRLAB Therapeutics AB

Net Sales

At SEK 39.36 MM has Grown at 174%

over average net sales of the previous four periods of SEK 14.37 MM

MOJO Watch

Near term sales trend is extremely positive

Net Sales (SEK MM)

Pre-Tax Profit

At SEK 9.12 MM has Grown at 133.17%

over average net sales of the previous four periods of SEK -27.5 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (SEK MM)

Net Profit

At SEK 9.12 MM has Grown at 133.17%

over average net sales of the previous four periods of SEK -27.5 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (SEK MM)

Net Sales

Highest at SEK 39.36 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (SEK MM)

Operating Profit

Highest at SEK 10.63 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (SEK MM)

Operating Profit Margin

Highest at 27 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at SEK 9.12 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (SEK MM)

Net Profit

Highest at SEK 9.12 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (SEK MM)

EPS

Highest at SEK 0.11

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (SEK)

Raw Material Cost

Fallen by -103.43% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for IRLAB Therapeutics AB

Cash and Eqv

Lowest at SEK 132.64 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents